Single Technologies

Executive Summary

Single Technologies is a Swedish genomics company pioneering 3-D Sequencing™, a disruptive platform that replaces traditional flat flow cells with a three-dimensional sample architecture. This innovation dramatically increases the number of DNA sequences read in parallel, overcoming the efficiency plateau of next-generation sequencing (NGS). By seamlessly integrating sequencing with spatial biology, the platform enables researchers to simultaneously obtain high-throughput genomic data and spatial context, offering unprecedented insights into tissue architecture, cellular heterogeneity, and biological function. Founded in 2018 and headquartered in Stockholm, the company is well-positioned to address the growing demand for spatially resolved genomics in research and clinical applications. While still in a private stage with no disclosed funding or valuation, Single Technologies has the potential to transform the sequencing landscape by significantly reducing cost and time while adding spatial information. The technology could accelerate discoveries in oncology, neuroscience, and developmental biology. However, the company faces challenges in scaling the platform, competing with established players like Illumina, and securing partnerships for commercialization. With the global spatial genomics market projected to grow rapidly, Single Technologies' differentiation could attract strategic investors and collaborators. The next 12-18 months are critical for demonstrating the platform's reliability and cost advantages through peer-reviewed studies and pilot programs.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Publication of Key Proof-of-Concept Study60% success
• Q1 2027Partnership with Major Research Institution50% success